News : Vitamin K2

OSLO, NORWAY -- NattoPharma ASA (NATTO: Oslo Axess) has announced that its product, MenaQ7Crystals brand vitamin K2 menaquinone-7 (MK-7), the leading MK-7 ingredient, has been selected as a finalist -- one of three -- for Nutrition Business Technology's "Most Effective Product Development Strategy category, as part of its annual awards program presented at Vitafoods, Europe's leading nutritional and food tradeshow.

4th April 2013, Oslo, Norway.  NattoPharma announces the appointment of Eric Anderson as Senior Vice President (SVP) Global Sales & Marketing.
In the newly established role as SVP, Eric Anderson will direct the global sales & marketing platform for NattoPharma’s proprietary products, including the MenaQ7® brand Vitamin K2 portfolio. In addition Anderson will create and maintain the North American headquarters...

3rd April 2013, OSLO, NORWAY – NattoPharma (NATTO: Oslo Axess) announces the appointment of Eric Anderson as Senior Vice President Global Sales & Marketing.
In this newly established role, Anderson will direct the global sales & marketing platform for NattoPharma’s proprietary products, including the MenaQ7® brand Vitamin K2 portfolio. Additionally, Anderson will create and maintain the North American...

3rd April 2013 Oslo, Norway.  NattoPharma announces today the publication of a new study on its proprietary MenaQ-7™ brand of Natural Vitamin K2 standardized to MK-7 content.  In the human trial, MenaQ7™ was shown to be a potent inhibitor of anticoagulant activity, a strong indicator of the protective benefits of natural K2 for vitamin k-dependent proteins. Interestingly, in this trial, vitamin K2 was shown to be...

26th March 2013 Oslo, Norway. NattoPharma announces today the publication of a ground-breaking new study on its proprietary MenaQ7® brand of Natural Vitamin K2 standardized to MK-7 content. The company initiated the three-year clinical intervention study on the effects of MenaQ7 on bone health and it is now available online in the leading journal Osteoporosis International as an Online First Article (DOI...

NattoPharma, the worldwide pioneer behind MenaQ7® and documentation of health effects of vitamin K-2, has announced it will expand its product portfolio with new products derived from biotechnology, fermentation and green technology.
While the main focus for NattoPharma until now has been on traditional natural vitamin K2 with extended research and development, the ingredient innovator will now include new...

OSLO, NORWAY (August 28, 2012) -- NattoPharma ASA, the worldwide innovator of MenaQ7, a proprietary and patented vitamin K2 menaquinone-7 derived from natto, has announced a key management position:  Hogne Vik, MD, PhD, MBA is the new CEO as selected by the Board of Directors of Nattopharma.
Frode M. Bohan, Executive Chairman of the Board for Nattopharma, said, “Dr Vik has previous experience at similar...

NattoPharma is pleased to announce that the company has signed a Commercial Sales Agent Agreement with Wilke Resources Inc. for sale of MenaQ7®, natural vitamin K2, in USA.
With this contract NattoPharma has established an important relationship and link into the important US market, where NattoPharma has filed several patents. Wilke Resources Inc. is working in the area of dietary supplement and nutraceutical...